Immutep Ltd

No revenue, EPS, gross margin, or year-over-year financial results were reported in this Q&A-only call segment. On guidance and operational planning, management said the ICS analysis is now focused on baseline-through-treatment response across all 63 patients, with a secondary look at how long the response can be maintained. For CANVAS, the protocol allows up to 120 sites, about 80 centers are identified, and roughly 50 are being targeted; management also said recruitment may range from about half to one patient per clinical center per month depending on location. Marc Voigt said the company holds significant euro and US dollar positions, has been seeing a $1.4 million to $1.5 million foreign exchange gain mentioned in the report, and maintains hedging contracts tied to projected ongoing operations.

Matthew Lehman’s tone was cautiously upbeat and promotional, emphasizing that the company is spending more time in the US introducing Prima to investors. He said the story is attractive because biotech is strong in the US right now and immunotherapy is gaining traction scientifically and financially. On communications, he said the company wants to keep telling its story but remain balanced and avoid over-communicating before more clinical data are available.

Marc Voigt focused on balance sheet and FX protection rather than operating metrics, saying the company holds significant euro and US dollar cash balances. He said that creates a buffer against Australian dollar weakness and that Prima continues to use hedging contracts based on projected ongoing operations. He also noted that most clinical operations run in Europe and the United States, which makes the current currency mix comparatively favorable.

The main technical question was about what the upcoming ICS test results should show versus last year’s release. Sharron Gargosky said last year’s data were only a small snapshot, while the new analysis will look at all 63 patients from baseline through dosing to see peak immune response and then, secondarily, how durable that response is. Other questions centered on increased NASDAQ trading volume and media strategy; management linked the volume to increased US investor outreach and said they are building visibility carefully, especially in Australia, while staying conservative about publicity until more trial data are available.